In another phase I study, patients with resected or locally advanced pancreatic cancer were given a synthetic MUC1 peptide vaccine with SB-AS2 adjuvant, followed by adjuvant therapy at the physician’s discretion. The gene discussed is MUC1; the disease is familial pancreatic carcinoma.